AST-3424

OBI-3424 (AST-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent; OBI-3424 is a nitro-benzene prodrug of N,N’-bisethylenephosphoramidate, demonstrates in vivo efficacy against preclinical xenograft models of pediatric T-ALL. Liver Cancer Phase 2 Clinical

References 1. Richard B. Lock, et al. Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study. AACR 2018. View Related Products by Target DNA Alkylator/Crosslinker Liver Cancer